 The Food and Drug Administration expanded the label for Novo Nordisks oral diabetes medicine, leading NVO stock to jump Friday. The post How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly appeared first on Investors Business Daily. 